Breaking Finance News

Epizyme Inc (NASDAQ:EPZM) target bumped up to $18.00, released a report earlier today by Zacks Investment Research

Having a price of $16.15, Epizyme Inc (NASDAQ:EPZM) traded -0.31% lower on the day. With the last close up 23.22% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. EPZM has recorded a 50-day average of $16.14 and a two hundred day average of $13.03. Trade Volume was down over the average, with 212,345 shares of EPZM changing hands under the typical 425,384

Reporting a potential upside of 0.11%, Zacks Investment Research upped the price target of Epizyme Inc (NASDAQ:EPZM) to $18.00

Recent Performance Chart

Epizyme Inc (NASDAQ:EPZM)

Epizyme Inc has with a one year low of $7.02 and a one year high of $18.50 and has a market capitalization of $0.

A total of 8 analysts have released a report on Epizyme Inc. Three analysts rating the company a strong buy, six analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a 12-month price target of $24.50.

General Company Details For Epizyme Inc (NASDAQ:EPZM)

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs). The Company develops small molecule inhibitors of other chromatin modifying proteins (CMPs). The Company's lead product candidate, tazemetostat, is a potent and selective inhibitor of the enhancer of zeste homolog 2 (EZH2) histone methyltransferases (HMT), an enzyme that plays an important role in various cancers. The Company is evaluating tazemetostat in a Phase II study in adults with relapsed or refractory non-Hodgkin lymphoma (NHL), and one Phase I study in children with molecularly defined solid tumors. The Company owns the global development and commercialization rights to tazemetostat outside of Japan.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *